Our study provides a platform for further mechanistic studies investigating the impact of ST6GAL1 and CD206+ macrophages in the prostate tumour immunosuppressive TME (for example in relation to T cell proliferation) and raises the possibility of enhancing therapies targeting prostate TAMs by concurrently blocking aberrant sialylation. Here, MRC1 is linked to prostate neoplasm.